Healthsens develops enzymatic and immunological biosensors, creating self-test and POCT (Point of Care Testing) devices for the diagnosis and monitoring of the major impact diseases affecting the worldwide population.
Enzymatic biosensor designed for the quantification of creatinine level in peripheral blood and estimation of the glomerular filtration rate (eGFR), making possible to have a comprehensive control over kidney disease, which is considered the third impact disease across the world.
POCT device for the early detection of prostate cancer (prostate health index PHI).
Bio-immunosensor that will analyze the biomarkers associated with prostate cancer with a single drop of patient’s serum. For the construction of these HEALTHSENS sensors a completely new methodology is being developed based on the use of magnetic nanoparticles.